<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122040</url>
  </required_header>
  <id_info>
    <org_study_id>54-282-14-3-2</org_study_id>
    <nct_id>NCT04122040</nct_id>
  </id_info>
  <brief_title>Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis</brief_title>
  <official_title>Effects of Roxithromycin on Quality of Life and Physiologic Outcomes in Bronchiectasis Patients During Treatment and Posttreatment Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological
      outcomes in bronchiectasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blinded, placebo controlled study was conducted to evaluate the effects
      of a 12-week administration of roxithromycin 300 mg once daily and a 12-week follow-up period
      in symptomatic stable bronchiectasis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2011</start_date>
  <completion_date type="Actual">September 30, 2011</completion_date>
  <primary_completion_date type="Actual">September 30, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomised control study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>block of 4</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SGRQ scores</measure>
    <time_frame>for 12 weeks</time_frame>
    <description>SGRQ scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary function tests</measure>
    <time_frame>24 weeks</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sputum volumes</measure>
    <time_frame>24 wekse</time_frame>
    <description>sputum volume per day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Quality of Life</condition>
  <condition>Respiratory Function Tests</condition>
  <arm_group>
    <arm_group_label>roxithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>roxithromycin 300 mg oral per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo one tablet per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roxithromycin 300 MG</intervention_name>
    <description>Roxithromycin 300 mg oral per day</description>
    <arm_group_label>roxithromycin</arm_group_label>
    <other_name>Roxithromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one table oral once dialy</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        minimum 15 year maximum 75 years

        Criteria inclusion Criteria:

        Symptomatic bronchiectasis Stable clinical bronchiectasis

        Exclusion Criteria:

        Adverse drug reaction to macrolide Recent exacerbation within 2 weeks History of macrolide
        therapy within 2 weeks active malignancy and end stage diseases 5. not perform lung
        function tests Females who were lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kanung Saejiam, MS</last_name>
    <role>Study Director</role>
    <affiliation>Prince of Songkla University</affiliation>
  </overall_official>
  <reference>
    <citation>Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, Mori M, Urano T, Sakamaki F, Tasaka S, Ishizaka A, Kanazawa M, Yamaguchi K. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J. 1999 Jun;13(6):1371-9.</citation>
    <PMID>10445614</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Siwasak Juthong</investigator_full_name>
    <investigator_title>Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>quality of life</keyword>
  <keyword>pulmonary function tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Roxithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

